BioRestorative Therapies, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective September 7, 2026. The company filed a Certificate of Change with the Secretary of State of Nevada to implement the split, which will reduce the number of issued and outstanding shares from approximately 27.6 million to about 1.38 million. The reverse split is intended to help the company regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The split will be effective at 4:30 p.m. Eastern Time on September 7, 2026. As a result, every 20 shares held immediately prior to the effective time will automatically convert into one share of common stock. The par value of the shares remains at $0.0001 per share. No fractional shares will be issued; instead, holders of record who would have received a fractional share will receive one whole share, rounded up to the nearest whole share.
In accordance with Nevada law, the number of authorized shares of common stock will be reduced proportionately from 1.5 billion to 75 million. Proportional adjustments will also be made to the number of shares issuable upon the exercise or vesting of outstanding stock options, warrants, and other equity-based awards, as well as to the applicable exercise or conversion prices. The company’s preferred stock authorization remains unchanged at 20 million shares.
Trading of the company’s common stock on The Nasdaq Capital Market will resume on a reverse split-adjusted basis at the opening of trading on September 8, 2026, under the existing trading symbol “BRTX” and a new CUSIP number, 090655705. The company noted that the reverse split will not alter any holder’s percentage ownership interest, except for de minimis changes resulting from the treatment of fractional shares.
